High Transaldolase 1 expression predicts poor survival of patients with upper tract urothelial carcinoma.
Transaldolase 1
immunohistochemistry
prognosis
upper tract urothelial carcinoma
Journal
Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
02
08
2020
accepted:
22
03
2021
pubmed:
14
4
2021
medline:
19
1
2022
entrez:
13
4
2021
Statut:
ppublish
Résumé
Upper tract urothelial carcinoma (UTUC) is a rare tumor with an incidence that varies greatly between Eastern and Western countries. Transaldolase 1 (TALDO1) is a rate-limiting enzyme of the pentose phosphate pathway. In humans, aberrant TALDO1 activity has been implicated in various autoimmune diseases and malignancies; however, the function of TALDO1 in UTUC has not been previously investigated. Here we evaluated the clinical significance of TALDO1 expression in 115 paraffin-embedded tumor samples from patients with UTUC using immunohistochemistry. Our results demonstrated that there was an association between high TALDO1 expression and advanced stage (P = 0.011), tumor size (P = 0.005), tumor location (P = 0.047), distant metastases (P = 0.023), local recurrence (P = 0.002), and cancer death (P = 0.003). Using univariate and multivariate analyses, we found that chemotherapy was an independent factor for bladder recurrence-free survival. Late stage (III/IV) and high TALDO1 expression were independent prognostic factors for progression-free and cancer-specific survival. In summary, increased TALDO1 expression in UTUC was significantly correlated with late stage, tumor size, tumor location, distant metastases, local recurrence, and cancer death. Therefore, high TALDO1 expression could be a predictor of poor survival in patients with UTUC. Further studies are necessary to investigate the role of TALDO1 in UTUC development.
Substances chimiques
Biomarkers, Tumor
0
Transaldolase
EC 2.2.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
463-470Subventions
Organisme : Ministry of Science and Technology
Organisme : Kaohsiung Medical University Hospital
Informations de copyright
© 2021 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Références
Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
Rouprêt M , Babjuk M , Compérat E et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018; 73: 111-22.
Cancer Registry Annual Report. In: Welfare HPAMOHA ed. 2018.12. Taiwan, 2015.
Nortier JL , Martinez MCM , Schmeiser HH et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000; 342: 1686-92.
Kardoust Parizi M , Glybochko PV , Enikeev D et al. Risk stratification of upper tract urothelial carcinoma: A review of the current literature. Expert Rev Anticancer Ther. 2019; 19: 503-13.
Patra KC , Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014; 39: 347-54.
Jin L , Zhou Y. Crucial role of the pentose phosphate pathway in malignant tumors. Oncol Lett. 2019; 17: 4213-21.
Samland AK , Sprenger GA. Transaldolase: From biochemistry to human disease. Int J Biochem Cell Biol. 2009; 41: 1482-94.
Silvers CR , Miyamoto H , Messing EM , Netto GJ , Lee YF. Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. Oncotarget 2017; 8: 91199-208.
Leduc CA , Crouch EE , Wilson A et al. Novel association of early onset hepatocellular carcinoma with transaldolase deficiency. JIMD Rep. 2014; 12: 121-27.
Yi H , Zheng X , Song J , Shen R , Su Y , Lin D. Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: A proteomics analysis. Int J Clin Exp Pathol. 2015; 8: 15719-28.
Yoo S , You D , Jeong IG et al. Impact of tumor location on local recurrence after nephroureterectomy for upper tract urothelial carcinoma: Implications for adjuvant radiotherapy. Clin Genitourin Cancer 2017; 15: e199-204.
Humphrey PA , Moch H , Cubilla AL , Ulbright TM , Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: Prostate and bladder tumours. Eur Urol. 2016; 70: 106-19.
Basta PV , Bensen JT , Tse CK , Perou CM , Sullivan PF , Olshan AF. Genetic variation in Transaldolase 1 and risk of squamous cell carcinoma of the head and neck. Cancer Detect Prev. 2008; 32: 200-208.
Kocevar N , Odreman F , Vindigni A , Grazio SF , Komel R. Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers. World J Gastroenterol. 2012; 18: 1216-28.
Ma Y , Peng J , Huang L , Liu W , Zhang P , Qin H. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis 2009; 30: 2591-99.
Wang C , Guo K , Gao D et al. Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples. Cancer Lett. 2011; 313: 154-66.
Kim YJ , Sertamo K , Pierrard MA et al. Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach. J Proteome Res. 2015; 14: 1412-19.
Garranzo-Asensio M , San Segundo-Acosta P , Povés C et al. Identification of tumor-associated antigens with diagnostic ability of colorectal cancer by in-depth immunomic and seroproteomic analysis. J Proteomics. 2020; 214: 103635.
Moriyama T , Tanaka S , Nakayama Y et al. Two isoforms of TALDO1 generated by alternative translational initiation show differential nucleocytoplasmic distribution to regulate the global metabolic network. Sci Rep. 2016; 6: 34648.
Mitsuishi Y , Taguchi K , Kawatani Y et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012; 22: 66-79.
DeNicola GM , Chen PH , Mullarky E et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet. 2015; 47: 1475-81.
DeNicola GM , Karreth FA , Humpton TJ et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106-109.
Sporn MB , Liby KT. NRF2 and cancer: The good, the bad and the importance of context. Nat Rev Cancer. 2012; 12: 564-71.
Nukui A , Narimatsu T , Kambara T et al. Clinically significant association of elevated expression of nuclear factor E2-related factor 2 expression with higher glucose uptake and progression of upper urinary tract cancer. BMC Cancer. 2018; 18: 493.